Laura Heraty

Laura Heraty

Auto-generated profile, based on publicly available information

Laura Heraty

UK Dementia Research Institute at Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAlvaro Murillo
Alvaro Murillo
MAMelanie Alpaugh
Melanie Alpaugh
RDRuban Rex Peter Durairaj
Ruban Rex Peter Durairaj
EREmma L. Randall
Emma L. Randall
MLMeghan Larin
Meghan Larin
VDVincent Dion
Vincent Dion
Expanded CAG/CTG repeats cause over 15 different diseases that all remain without a disease-modifying treatment. Because repeat length accounts for most of the variation in disease severity, contracting them presents an attractive therapeutic avenue. Here, we show that the CRISPR-Cas9 nickase targeted to CAG/CTG repeats leads to efficient contractions in Huntington’s disease patient-derived neurons and astrocytes, and in myotonic dystrophy type 1 patient-derived neurons. The approach is allele-selective and free of detectable off-target mutations. Striatal injection of the Cas9 nickase in a mouse model for Huntington’s disease using adeno-associated viral vectors led to contractions in over half the infected cells. Upon injection, we observed a reduction in the number of inclusion bodies, improved transcriptome, and ameliorated locomotion. The effects were greater than expected from the contractions induced and suggest that non-cell autonomous mechanisms may be involved. Our results provide the proof-of-concept that correction of CAG/CTG repeats can improve Huntington’s disease phenotypes in vivo . One sentence summary: The Cas9 nickase contracts CAG/CTG repeats at multiple disease loci in patient-derived cells and improves molecular and behavioral phenotypes in HD.

15 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CSChristopher Smith
Christopher Smith
RDRuban Rex Peter Durairaj
Ruban Rex Peter Durairaj
EREmma L. Randall
Emma L. Randall
AAAlys N. Aston
Alys N. Aston
LHLaura Heraty
Laura Heraty
VDVincent Dion
Vincent Dion
The expansion of short tandem repeats is a feature of over 60 different human diseases. Ongoing somatic instability throughout a patient’s lifetime can influence disease progression and has emerged as a therapeutic target. Understanding its mechanism is essential for the identification of both drug targets and therapeutic interventions. A major obstacle towards this translational goal has been to measure changes in repeat size distribution given that these are complex datasets. To address this, here we provide a new analysis method, and accompanying software, that generates delta plots, extracts the instability frequency from targeted long-read sequencing data, the bias towards expansion or contraction, and the average size of the changes. It further provides statistical analysis for comparison between treatments. We show its applicability to non-dividing cells, and in vivo datasets. Moreover, we have developed a streamlined experimental design for dividing cells, Single Clone-based Instability Assay (SCIA), that saves weeks in assessing the effect of a gene knockout on repeat instability and is ideal for an initial screen. We have validated the approach using FAN1, PMS1, and MLH1 knockouts. Using SCIA, we find that although FAN1 knockout clones showed increased frequency of expansions, the size of the expansions were smaller. This highlights the wealth of information that can be extracted and the potential for novel insights into the mechanism of repeat instability.

21 October 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
AMAlvaro Murillo
Alvaro Murillo
MAMelanie Alpaugh
Melanie Alpaugh
RDRuban Rex Peter Durairaj
Ruban Rex Peter Durairaj
EREmma L. Randall
Emma L. Randall
MLMeghan Larin
Meghan Larin
VDVincent Dion
Vincent Dion
Expanded CAG/CTG repeats cause more than 15 different diseases that all remain without a disease-modifying treatment. Because repeat length accounts for most of the variation in disease severity, contracting CAG/CTG repeats presents an attractive therapeutic avenue. Here, we show that the CRISPR-Cas9 nickase targeted to CAG/CTG repeats leads to efficient repeat contractions in Huntington’s disease (HD) patient–derived neurons and astrocytes and in myotonic dystrophy type 1 patient–derived neurons. The approach was allele selective and free of detectable off-target mutations. Injection of the Cas9 nickase into the striatum of the R6/1 mouse model of HD using adeno-associated viral vectors led to repeat contractions in more than half of striatal neurons. Upon injection, we observed a reduction in the number of inclusion bodies, an improved gene expression profile, and amelioration of locomotion deficits in the open field test. The effects were greater than expected from the contractions induced, suggesting that non–cell autonomous mechanisms may be involved. Our results provide the proof of concept that correction of CAG/CTG repeats can improve HD phenotypes in a mouse disease model.

5 September 2021 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Conference Paper
Closed access
PDF file
LHLaura Heraty
Laura Heraty
VDVincent Dion
Vincent Dion
Background Longer CAG repeats in the HTT gene causes more severe forms of Huntington’s disease (HD), suggesting that contracting them would provide a much needed therapeutic benefit. We developed the first method to contract expanded repeats in human cell lines, whilst avoiding concomitant expansions. Unlike other systems that induce double strand breaks around the repeat tract to remove the repeat region, our method relies on the CRIPSR Cas9 nickase. The enzyme is targeted by a guide RNA against the repeat tract, resulting in nicks that are processed by the endogenous DNA repair machinery leading to contractions. The mechanism of contraction is poorly defined and identifying genetic players is important for both improving the contraction efficacy and for stratifying which patients would benefit best from this therapy. Aims Here we tested the hypothesis that loss of FAN1 impacts nickase-induced contractions. Methods/Techniques We generated a HEK293-derived cell line which contains a stably integrated CRISPR-Cas9 nickase, a sgRNA against the repeat tract and an inducible GFP-reporter system containing an ectopic CAG repeat. In this line, we also knocked out FAN1. We assayed for FAN1 loss of function using targeted DNA sequencing, western blotting, and sensitivity to mitomyocin C. We analysed repeat size using flow cytometry for GFP expression and by small-pool PCR. Results/Outcomes We found that two independent FAN1 knockout clones displayed an increase in the frequency of contraction events over 21 days. We found no effect on the frequency of expansion. Conclusions We conclude that FAN1 in our system prevents nickase-induced contractions without impacting expansion events.

26 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AHAeverie E.R. Heuchan
Aeverie E.R. Heuchan
RDRuban R Peter Durairaj
Ruban R Peter Durairaj
AAAlys N Aston
Alys N Aston
EREmma L Randall
Emma L Randall
LHLaura Heraty
Laura Heraty
VDVincent Dion
Vincent Dion
Expanded repeat disorders remain without a disease modifying treatment. Some of the most important modifiers of disease severity include inherited repeat size, their somatic mosaicism, and whether they contain interruptions. Targeted sequencing approaches are becoming the gold standard on how these parameters are measured despite repeats being notoriously challenging to sequence. Here we developed CHARLIE (Comprehensive High-throughput Analysis of Repeat Length, Interruptions and Expansions) to identify and position interruptions within expanded repeats. We used samples from Huntington's disease and myotonic dystrophy type 1 sequenced with Illumina MiSeq and PacBio's Single-Molecule Real-Time Sequencing. We validated the pipeline against previous methods for identifying germline-inherited interruptions. One challenge that can potentially mask the identification of true interruptions and sequence variation is the accuracy of sequencing platforms, which, when applied to expanded repeats, is largely unknown. Our results suggest that each sequencing platform produces a distinct error profile and we show that PCR-free library preparation for SMRT sequencing improves sequencing accuracy. CHARLIE, therefore, provides a method that can help differentiate between trivial sequencing errors and those interruptions that modify disease presentation, which can be inherited or somatic in origin.